Boceprevir: A User's Guide

Clinics in Liver Disease

Volumn 15, Issue 3, 2011, Pages 537-553

  Kwo, Paul Y ^a   Zhao, Rong ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Boceprevir; Direct acting antiviral; Hepatitis C virus; Protease inhibitor; Resistance

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR;

AFRICAN AMERICAN; ANEMIA; ANTIVIRAL ACTIVITY; COMBINATION CHEMOTHERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; GENOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL GENETICS; VIRUS RESISTANCE; VOMITING;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; VIRAL NONSTRUCTURAL PROTEINS;

EID: 80051951128     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.05.005     Document Type: Review

References (33)

1. Thomas D.L. Hepatitis C. Epidemiologic quandaries. Clin Liver Dis 2001, 5(4):955-968.
2. Verna E.C., Brown R.S. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006, 10(4):919-940.
3. Lauer G., Walker B. Hepatitis C virus infection. N Engl J Med 2001, 345(1):41-52.
4. Wasley A., Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000, 20(1):1-16.
5. Penin F., Dubuisson J., Rey F.A., et al. Structural biology of hepatitis C virus. Hepatology 2004, 39(1):5-19.
6. Nielsen S.U., Bassendine M.F., Burt A.D., et al. Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J Gen Virol 2004, 85(Pt 6):1497-1507.
7. Pisarev A.V., Shirokikh N.E., Hellen C.U. Translation initiation by factor-independent binding of eukaryotic ribosomes to internal ribosomal entry sites. C R Biol 2005, 328(7):589-605.
8. Lee G., Piper D.E., Wang Z., et al. Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases. J Mol Biol 2006, 357(4):1051-1057.
9. Biswal B.K., Wang M., Cherney M.M., et al. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition. J Mol Biol 2006, 361(1):33-45.
10. Kunkel M., Lorinczi M., Rijnbrand R., et al. Self-assembly of nucleocapsid-like particles from recombinant hepatitis C virus core protein. J Virol 2001, 75(5):2119-2129.
11. McHutchison J.G., Lawitz E.J., Shiffman M.L., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361(6):580-593.
12. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):958-965.
13. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13):975-982.
14. Sulkowski M. Treatment of hepatitis C in HIV-infected persons: a work in progress. J Hepatol 2008, 48(1):5-7.
15. Conjeevaram H.S., Fried M.W., Jeffers L.J., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131(2):470-477.
16. Muir A.J., Bornstein J.D., Killenberg P.G., et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350(22):2265-2271. [see comment] [Erratum appears in N Engl J Med 2004;351(12):1268].
17. Mangia A., Minerva N., Bacca D., et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008, 47(1):43-50.
18. Bartenschlager R. Hepatitis C virus replicons: potential role for drug development. Nat Rev Drug Discov 2002, 1(11):911-916.
19. Llinas-Brunet M., Bailey M.D., Bolger G., et al. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. J Med Chem 2004, 47(7):1605-1608.
20. Steinkuhler C., Biasiol G., Brunetti M., et al. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 1998, 37(25):8899-8905.
21. Ingallinella P., Altamura S., Bianchi E., et al. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry 1998, 37(25):8906-8914.
22. Lohmann V., Körner F., Koch J., et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285(5424):110-113.
23. Pause A., Kukolj G., Bailey M., et al. An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J Biol Chem 2003, 278(22):20374-20380.
24. Hinrichsen H., Benhamou Y., Wedemeyer H., et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004, 127(5):1347-1355.
25. Lamarre D., Anderson P.C., Bailey M., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426(6963):186-189.
26. Malcolm B.A., Liu R., Lahser F., et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006, 50(3):1013-1020.
27. Sarrazin C., Rouzier R., Wagner F., et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007, 132(4):1270-1278. [see comment].
28. Sarrazin C., Kieffer T.L., Bartels D., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132(5):1767-1777.
29. Schiff E., Poordad E., Jacobson I., et al. Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness. J Hepatol 2008, 48:S46.
30. Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376(9742):705-716.
31. Sulkowski M., Shiffman M.L., Afdhal N.H., et al. Decline in hemoglobin is associated with sustained virologic response (SVR) among HCV genotype 1-infected persons treated with peginterferon (PEG)/ribavirin (RBV): analysis from the ideal study. Gastroenterology 2010, 139:1602-1611.
32. Poordad F., McCone J., Bacon B., et al. Boceprevir with peginterferon/ribavirin for untreated chronic hepatitis C. N Engl J Med 2011, 364:1195-1206.
33. Bacon B., Gordon S., Lawitz E., et al. Boceprevir for treatment-resistant chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.